Witryna12 kwi 2024 · Streubesitz. 99,9%. Mehr Finanzkennziffern. Unternehmensprofil. Organon & Co. (Organon) ist ein globales Gesundheitsunternehmen. Das Unternehmen ist in der Entwicklung und Bereitstellung von Gesundheitslösungen durch ein Portfolio von verschreibungspflichtigen Therapien im Bereich der Frauengesundheit, Biosimilars … Witryna4 sie 2024 · Additionally, Organon will likely pay out about 20% of its free cash flow in dividends, providing what we estimate will be a 2.7% yield. The shares trade at 4.9x estimated 2024 earnings of $6.25 ...
全球女性健康公司Organon问世 Business Wire
Witryna13 cze 2024 · Organon CEO Kevin Ali said in a statement, “Biosimilars are a key growth pillar for Organon, and this collaboration represents the successful execution of our strat ... WitrynaWszystkie produkty producenta Organon w i-Aptece! * Przed użyciem leków zapoznaj się z jego ulotką, która zawiera wskazania, przeciwskazania, dane dotyczace działań … system.io.directory.getfiles 複数条件
Investor relations Organon
WitrynaOur presence in the UK goes back a long way. For over 80 years, we’ve been researching, developing and supplying new medicines and vaccines that prevent and treat diseases that occur at every stage of life. As a global company, for over 125 years MSD has been guided by the conviction that great medicines change the world. WitrynaOrganon is a global healthcare company formed through a spinoff from Merck (known as MSD outside of the U.S. and Canada) with a mission to deliver impactful medicines and solutions for a healthier every day. ... Corporate Members receive a listing in our Member Directory, the right to nominate up to 10 representatives, and 8 vouchers that may ... WitrynaOur areas of focus. Our portfolio encompasses more than 60 medicines and products across a range of areas including reproductive health, heart disease, oncology, … system.io.directory.getfiles 順番